Varicella vaccination in Italy : an economic evaluation of different scenarios

PharmacoEconomics
Laurent CoudevilleBenoit Dervaux

Abstract

To determine the economic impact (cost-benefit analysis) of childhood varicella vaccination, with the Oka/Merck varicella zoster virus vaccine live (Varivax) in Italy. This analysis is based on an epidemiological model of varicella zoster virus (VZV) dynamics adapted to the Italian situation. Cost data (Euro, 2002 values) were collected through a literature review. Several vaccination scenarios were analysed: (i) routine vaccination programme for children aged 1-2 years with different levels of vaccination coverage (90%, 70% and 45%) without any catch-up programme; (ii) routine vaccination programme for children aged 1-2 years with different levels of vaccination coverage (90%, 70% and 45%) completed by a catch-up programme for 6-year-old children over the first 5 years of vaccine marketing; and (iii) routine vaccination programme for children aged 1-2 years with different levels of vaccination coverage (90%, 70% and 45%) completed by a catch-up programme during the first year of vaccine marketing for children aged 2-11 years. A societal perspective, including both direct and indirect costs, and a health-system perspective, limited to costs supported by Italian Health Authorities, were considered. A routine vaccination programm...Continue Reading

References

Jan 1, 1985·Medical Decision Making : an International Journal of the Society for Medical Decision Making·P DoubiletB J McNeil
Oct 1, 1985·The Journal of Hygiene·B T Grenfell, R M Anderson
Sep 1, 1995·The Journal of Infectious Diseases·P W ChooR Platt
Jun 1, 1994·The Journal of Pediatrics·D M HuseG Oster
Feb 2, 1994·JAMA : the Journal of the American Medical Association·T A LieuA E Washington
Sep 1, 1996·Infectious Disease Clinics of North America·D A Clements
Sep 1, 1996·Infectious Disease Clinics of North America·M E Halloran
May 1, 1997·The Journal of Pediatrics·B P YawnE Lydick
Nov 18, 1997·Epidemiology and Infection·A M GrayA McGuire
Nov 18, 1997·JAMA : the Journal of the American Medical Association·H S IzurietaP A Blake
Apr 9, 1999·Vaccine·J Díez DomingoA Morant
Oct 16, 1999·Vaccine·P A ScuffhamM A Burgess
Dec 23, 1999·The Pediatric Infectious Disease Journal·S BlackH Guess
Jul 29, 2000·The Journal of Infectious Diseases·P A MeyerM Wharton
Dec 15, 2000·Vaccine·R G SharrarA A Gershon
Jan 4, 2001·The Journal of Adolescent Health : Official Publication of the Society for Adolescent Medicine·Z HarelP Flanagan
Feb 24, 2001·Epidemiology and Infection·M BrissonG De Serres
May 5, 2001·Epidemiology·M A HernánA Ascherio
Jul 27, 2001·Epidemiology and Infection·G GabuttiUNKNOWN Serological Study Group
Nov 10, 2001·BMJ : British Medical Journal·H RawsonN Noah
Jan 23, 2002·Vaccine·M Brisson, W J Edmunds
Feb 7, 2002·JAMA : the Journal of the American Medical Association·Jane F SewardMelinda Wharton
Aug 17, 2002·The Pediatric Infectious Disease Journal·Denis GetsiosJean-Marie R Lance
Dec 18, 2002·PharmacoEconomics·Nancy ThiryEddy Van Doorslaer
Feb 15, 2003·The Journal of Hospital Infection·J O'Neill, J Buttery
Mar 13, 2003·Euro Surveillance : Bulletin Européen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin·Daniel Levy-BruhlK Osborne
May 8, 2003·American Journal of Infection Control·Hung-Fu TsengChen-Kang Chang
Sep 23, 2003·Archives of Disease in Childhood·M Brisson, W J Edmunds

❮ Previous
Next ❯

Citations

Mar 3, 2004·Archives de pédiatrie : organe officiel de la Sociéte française de pédiatrie·H BruelJ Beurrier
Jan 6, 2006·The Pediatric Infectious Disease Journal·Markus KnufPaul Willems
Jan 7, 2006·The Pediatric Infectious Disease Journal·Richard D RheingansCarlo Giaquinto
Jul 21, 2012·Expert Review of Pharmacoeconomics & Outcomes Research·Josephine MauskopfBaudouin Standaert
Jul 31, 2008·Expert Review of Vaccines·Mark H RozenbaumMaarten J Postma
Dec 2, 2008·Gynecologic Oncology·F S MenniniN Largeron
Dec 22, 2015·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Katrin HaeusslerGianluca Baio
Dec 23, 2006·Risk Analysis : an Official Publication of the Society for Risk Analysis·Kimberly M Thompson, Radboud J Duintjer Tebbens
Jan 1, 2015·Journal of Market Access & Health Policy·Walter Ricciardi, Mondher Toumi
Jan 1, 2015·Journal of Market Access & Health Policy·Maarten J PostmaAlexandra Brandão
Jul 5, 2013·Human Vaccines & Immunotherapeutics·Brigid UnimGiuseppe La Torre
May 10, 2005·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Laurent CoudevilleBenoit Dervaux
Jun 24, 2016·Euro Surveillance : Bulletin Européen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin·Sara BoccaliniAngela Bechini
Sep 15, 2016·International Journal of Technology Assessment in Health Care·Silvia CorettiAmerico Cicchetti
Jan 21, 2010·Cadernos de saúde pública·Patrícia Coelho de SoárezAna Marli Christovan Sartori
Nov 9, 2018·The Pediatric Infectious Disease Journal·Vana SpoulouTimo Vesikari
Sep 25, 2020·Expert Review of Vaccines·Florence KauffmannPeter Wutzler
Jul 2, 2020·ClinicoEconomics and Outcomes Research : CEOR·C AzzariL J Wolfson
May 8, 2008·Central European Journal of Public Health·Napoleon Perez-FarinosMaria Ordobas

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.